NasdaqCM - Nasdaq Real Time Price USD

Oncolytics Biotech Inc. (ONCY)

1.0350 +0.0050 (+0.48%)
As of 12:18 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Matthew C. Coffey M.B.A., Ph.D. President, CEO & Director 787.04k -- --
Mr. Kirk J. Look C.A., CA Chief Financial Officer 550.02k -- --
Dr. Thomas C. Heineman M.D., Ph.D. Chief Medical Officer 605.87k -- --
Ms. Allison Hagerman P.Eng., P.M.P. Vice President of Product Development 417.82k -- --
Jon Patton Director of Investor Relations & Communication -- -- --
Mr. John Mark Lievonen BBA, C.M., FCA, LLD, MBA Consultant 18.86k -- --

Oncolytics Biotech Inc.

322 11th Avenue SW
Suite 804
Calgary, AB T2R 0C5
Canada
403 670 7377 https://www.oncolyticsbiotech.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Corporate Governance

Oncolytics Biotech Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 5; Board: 1; Shareholder Rights: 2; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 03, 2024 - May 07, 2024
Oncolytics Biotech Inc. Earnings Call

Related Tickers

TNYA Tenaya Therapeutics, Inc.
4.2300
-1.40%
 
VBIV VBI Vaccines Inc.
0.6487
+3.02%
 
OCUP Ocuphire Pharma, Inc.
1.6700
0.00%
 
SCPH scPharmaceuticals Inc.
4.5800
+1.55%
 
LYRA Lyra Therapeutics, Inc.
5.45
+1.11%
 
PGEN Precigen, Inc.
1.3000
-1.52%
 
XERS Xeris Biopharma Holdings, Inc.
1.7107
-2.80%
 
MIST Milestone Pharmaceuticals Inc.
1.6602
+1.85%
 
HOOK HOOKIPA Pharma Inc.
0.7510
-1.76%
 
CYCC Cyclacel Pharmaceuticals, Inc.
1.8799
+1.07%